The GNAI2 knockout HEK293T polyclonal cells constitute a genetically modified cell population generated through CRISPR/Cas9-mediated disruption of the human GNAI2 gene. This product is delivered as a polyclonal pool of edited HEK293T cells, offering a loss-of-function model without single-cell clonal selection. The polyclonal format retains population-level heterogeneity, which can buffer against clonal artifacts and provides robust material for functional genomic studies. The targeted disruption ablates expression of the G??i2 protein, enabling researchers to interrogate its roles across diverse signaling contexts. Suitable for transient and stable downstream applications, these cells serve as a foundational tool for dissecting inhibitory G-protein signaling.
The host cell line, HEK293T, is a widely employed derivative of human embryonic kidney 293 cells that stably expresses the SV40 large T antigen. This modification enhances episomal replication of plasmids containing the SV40 origin of replication, resulting in exceptional transfection efficiency and high recombinant protein yields. The epithelial origin and robust growth characteristics of HEK293T cells make them particularly suited for signaling studies, receptor overexpression, and large-scale biochemical analyses. Their established use in GPCR pharmacology and cancer biology provides a reliable background for evaluating GNAI2-dependent phenotypes, with the added advantage of facile manipulation via standard lipid-based transfection methods.
GNAI2 encodes the alpha subunit of the heterotrimeric Gi2 protein, a critical inhibitor of adenylyl cyclase downstream of numerous G protein-coupled receptors (GPCRs). Upon receptor activation, G??i2 decreases intracellular cAMP levels, thereby attenuating protein kinase A (PKA) activity and modulating phosphodiesterase function. The Gi2 signaling network integrates inputs from diverse upstream regulators such as chemokine receptors CXCR4 and CCR5, adrenergic receptors, dopamine receptors, and opioid receptors, while its actions are fine-tuned by regulators of G-protein signaling (RGS) proteins. Beyond cAMP suppression, G??i2 directly engages PI3K/AKT and MAPK/ERK pathways through G?¦? subunits, linking GPCR activation to cell migration, proliferation, and survival. The protein interacts with adenylyl cyclase isoforms, PI3K, and G-protein-coupled inwardly rectifying potassium (GIRK) channels, forming a node that coordinates multiple intracellular cascades.
In the HEK293T context, CRISPR/Cas9-mediated knockout of GNAI2 permits direct assessment of Gi2 contributions to signaling dynamics and cellular behavior. Because these cells endogenously express a wide array of GPCRs, the model facilitates evaluation of receptor-specific Gi2 coupling without the need for exogenous receptor overexpression, though engineered receptor expression can further refine experimental design. The loss of G??i2 disrupts canonical cAMP inhibition and alters downstream PI3K and ERK activity, providing a clean background for studying compensatory mechanisms or validating isoform-specific functions. This system is highly relevant for cancer research, as GNAI2 has been implicated in hepatocellular carcinoma, colorectal cancer, and glioblastoma, where Gi2-mediated signals influence tumor cell migration and invasion.
Research applications for these polyclonal knockout cells are extensive and include GPCR signal transduction analysis, functional genomics screens, and drug target validation. Representative assays compatible with this model encompass quantitative western blotting and RT-qPCR to confirm protein and transcript loss, cAMP accumulation measurements to gauge adenylyl cyclase activity, phospho-AKT and phospho-ERK detection via flow cytometry or immunoblotting, and cell migration/invasion assays such as Boyden chamber or wound-healing. The cells are also amenable to live-cell imaging and high-throughput screening platforms. For further details or to discuss custom applications, please contact Ascent Research.
